Skip to content

Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor

Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05742997
Acronym
PartoSure
Enrollment
165
Registered
2023-02-24
Start date
2021-10-01
Completion date
2023-10-31
Last updated
2023-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Brief summary

Currently, the American College of Obstetricians and Gynecologists (ACOG) indicate in their most recent Practice Bulletin on the Management of Preterm Labor that many tests to identify women at risk of preterm birth have been proposed and evaluated; however, only ultrasonography and fetal fibronectin testing have been shown to have benefit. Ultrasonography to determine cervical length, fetal fibronectin testing, or a combination of both may be useful in determining which women are at high risk for preterm delivery. However, their clinical usefulness may rest primarily with their ability to identify women who are least likely to deliver (i.e. their negative predictive value). Therefore, there is an urgent need for a test with a high positive predictive value in order to accurately predict imminent delivery to allow for salutary intervention.

Interventions

DEVICEPartoSure

Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1

DEVICEFetal Fibronectine

Diagnostic Kit for the Detection of Fetal Fibronectine

Sponsors

Ziekenhuis Oost-Limburg
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients presenting for emergency obstetrical care at an emergency room or labor & delivery unit with signs, symptoms or complaints suggestive of preterm labor (PTL) * Uterine contractions, with or without pain * Intermittent lower abdominal pain * Dull backache * Pelvic pressure * Bleeding during the second or third trimester * Menstrual-like or intestinal cramping, with or without diarrhea * Patient is not feeling right * Gestational age between 200/7 and 366/7 * Consenting to be part of the trial

Exclusion criteria

* Presented for regularly scheduled obstetrical care with symptoms * \< 18 years old and not emancipated consenting minor * \< 200/7 weeks of gestation or ≥ 37 weeks of gestation cervix length \> 30 mm * cervical dilatation \> 3 centimeters * overt rupture of the fetal membranes (ROM) as indicated by visualized leakage of fluid from the cervical os * heavy vaginal bleeding * received tocolytic medications for treatment of threatened preterm delivery prior to collection of the cervicovaginal specimens or cervical length measurements * suspected placenta previa * cervical cerclage in place * a symptom not associated with idiopathic threatened preterm delivery (e.g. trauma) * digital exam prior to specimen collection

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive value48 hoursSensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) for the kit for the detection of PAMG-1, cervical length measurements by trans-vaginal ultrasound (\<30 mm), and contraction frequency ≥ 8 per hour.

Countries

Belgium

Contacts

Primary ContactCaroline Van Holsbeke, MD, PhD
caroline.vanholsbeke@zol.be003289327521
Backup ContactEls Papy, Msc
els.papy@zol.be0032889327530

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026